The clinical experience with analogues of rapamycin that have been tested as cancer therapeutics is consistent with these preclinical observations, in that mTOR inhibitors only have modest activity as single agents in patients with advanced lung cancer [32], [33]. This evidence concerns the gene MTOR and lung cancer.